Despite the current focus on genomics and transcriptomics, these technologies can fail to accurately predict which patients will respond to a therapy. As the ultimate readout of the state of cells and tissues, proteomics offers the most accurate representation of patient phenotype and the best predictive power.

In this white paper, we outline the differences between mass spectrometry and affinity-based techniques for large-scale plasma proteomics, explaining the advantages, applications, and recent developments in mass spectrometry that make it the most robust proteomics technology for true discovery research.